Clinical Trial Update: [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis [NA]

View source ↗

Summary

The trial evaluating the radiolabeled imaging agent [18F]Dabrafenib for detecting melanoma brain metastases has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Dabrafenib (Dabrafenib)
• [18F]Dabrafenib (Dabrafenib)

Snippet

Sponsor: University Medical Center Groningen | Conditions: Melanoma | NA | Status: TERMINATED